Beyond Medical Technologies Announces Marketing Initiatives

Beyond Medical Technologies Announces Marketing Initiatives

Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM4) ("Beyond Medical" or the "Company") is pleased to announce that it has entered into an online marketing agreement ("AGORA Agreement") with AGORA Internet Relations Corp. ("AGORA") and an investor marketing agreement (the "INN Agreement") with Dig Media Inc.® dba as Investing News Network® ("INN").

AGORA Internet Relations Corp.

Pursuant to the terms and conditions of the AGORA Agreement, AGORA will assist the Company with its launch of a 12 month online marketing campaign through AGORACOM for the purposes of targeting new potential investors that would be specifically interested in the Company's business model, as well as engaging current shareholders. AGORA will also assist the Company with ad placements and other branding initiatives which will be posted on AGOROCOM and distributed on YouTube, various social media platforms, and all podcast platforms.

The Beyond Medical HUB, located on AGORACOM, will contain multiple landing pages, videos, photos, and other helpful information about the Company updated in real time. The Beyond Medical HUB can be located at: https://agoracom.com/ir/BeyondMedicalTechnologies. Additionally, the Company has also launched a "CEO Verified" Discussion Forum on AGORACOM to serve as the Company's primary social media platform to interact with both current and prospective shareholders in a fully moderated environment.

The Beyond Medical discussion forum can be found at: https://agoracom.com/ir/BeyondMedicalTechnologies/forums/discussion

In connection with the services provided by AGORA under the AGORA Agreement, the Company will pay AGORA aggregate consideration of $100,000 plus applicable taxes, which shall paid via the issuance of common shares in the capital of the Company (the "PaymentShares"). The Payment Shares will be issued in five installments throughout the term of the AGORA Agreement, which commenced on November 29, 2021 and ends on December 30, 2022. The number and deemed price of the Payment Shares to be issued will be calculated using the closing price of the Company's common shares on the Canadian Securities Exchange on each date on which the Payment Shares are to be issued.

AGORA is the pioneer of online marketing, broadcasting, conferences and investor relations services to North American small and mid-cap public companies, with more than 300 companies served. AGORACOM is the home of more than 7.7 million investors that visited 55.2 million times and read over 600 million pages of information over the last 10 years. The average visit of 8min 43sec is more than double that of global financial sites, which can be attributed to the implementation and enforcement of the strongest moderation rules in the industry. AGORA's contact information is as follows: AGORA Internet Relations Corp., 155 East Beaver Creek Road, Unit 24, Suite 304, Richmond Hill, ON, L4B 2N1.

Investing News Network

The Company has also engaged INN, a British Columbia corporation, to provide an advertising and investor awareness campaign. INN will feature the Company's news and logo on its channel homepage as well as use its social media channels to bring attention to the Company's news.

The Company will pay INN aggregate consideration of $52,200 plus applicable taxes (the "INN Consideration"). The Company has agreed to pay the INN Consideration in three equal instalments of $17,400 plus applicable taxes, with the first payment payable on receipt of an invoice from INN. The second and third payments will be due on February 29, 2022 and May 29, 2022, respectively. The term of the INN Agreement is thirteen months, ending on December 30, 2022.

INN is a private company headquartered in Vancouver, Canada, dedicated to providing independent news and education to investors since 2007. INN does not provide Investor Relations or Market Making services. INN's contact information is as follows: Dig Media Inc.® d/b/a Investing News Network®, Suite L200, 560 Beatty Street, Vancouver, BC V6B 2L3.

About Beyond Medical

Beyond Medical is an industrial/technology company with a manufacturing facility located in Delta, B.C. The Company, through its subsidiary Micron Technologies, manufactures medical grade face masks. For further information contact:

Kal Malhi, CEO
604-805-4602
kal@bullruncapital.ca

The Company is not making any express or implied claims that its products have the ability to eliminate, cure or contain COVID-19 (or SARS-2 Coronavirus) at this time.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release. The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.

FORWARD-LOOKING STATEMENTS:

This news release includes certain statements that may be deemed "forward-looking statements". All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/106708

News Provided by Newsfile via QuoteMedia

DOCT:CNX
The Conversation (0)
Beyond Medical Provides Corporate Update

Beyond Medical Provides Corporate Update

Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM4) (OTC Pink: DOCKF) ("Beyond Medical" or the "Company") is pleased to provide a corporate update on its medical face mask manufacturing subsidiary Micron Technologies Inc. ("Micron Technologies").

The Company is reviewing Micron Technologies' medical face mask manufacturing business as many jurisdictions have recently lifted mask mandates and as demand for face masks rapidly declines. The Company is considering operating Micron Technologies' facility at reduced capacity or potentially terminating its mask manufacturing business via a sale of all inventory and equipment related to its mask manufacturing business and to seek new business opportunities.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Beyond Medical Subsidiary Micron Technologies Achieves "Amazon's Choice" Designation and Begins to Accept Bitcoin Payments for its Made in Canada Face Masks

Beyond Medical Subsidiary Micron Technologies Achieves "Amazon's Choice" Designation and Begins to Accept Bitcoin Payments for its Made in Canada Face Masks

Beyond Medical Technologies Inc. (" Beyond Medical " or the " Company ") (CSE: DOCT) ( Frankfurt : 7FM4) is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. (" Micron Technologies ").

Taking Healthcare Beyond Traditional Platforms (CNW Group/Beyond Medical Technologies Inc.)

"Amazon's Choice" Designation for Medical Grade Face Masks

Micron Technologies has been operating at the Company's facility in Delta, British Columbia since August 2020 where it manufactures three-ply medical grade face masks. In early April 2021 , Micron Technologies' three-ply medical grade face masks achieved the "Amazon's Choice" designation from Amazon. The "Amazon's Choice" designation is achieved by having a high star rating, competitive price, low return rate, consistent inventory, and high sales. Micron Technologies anticipates a sales boost following achieving the "Amazon's Choice" designation.

In addition to Amazon, Micron Technologies' products are available online at Walmart and Shopify. Institutional customers and those who are interested in obtaining a quote for large size orders are encouraged to contact Milan@micronti.com .

Micron Technologies Accepting Bitcoin

Micron Technologies has entered the cryptocurrency space by now accepting Bitcoin as a form of payment for its products. The option to pay with Bitcoin is available to both retail and wholesale customers. Customers who wish to pay with Bitcoin can do so on Micron Technologies' website where the payment will be completed via BitPay, a Bitcoin service provider.

About Beyond Medical

Beyond Medical is an industrial/technology company with a manufacturing facility located in Delta, British Columbia . The Company is developing its Organivore and Pharmavore waste digesters using its proprietary technology.

The Company, through its subsidiary Micron Technologies, is also manufacturing medical grade face masks.

The Company is not making any express or implied claims that its products have the ability to eliminate, cure or contain COVID-19 (or SARS-2 Coronavirus) at this time.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release. The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.

FORWARD LOOKING STATEMENTS:

This news release includes certain statements that may be deemed "forward-looking statements". All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

SOURCE Beyond Medical Technologies Inc.

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/April2021/27/c4406.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Beyond Medical Manufactures N95 Medical Face Masks as Third Wave of COVID-19 Surges

Beyond Medical Manufactures N95 Medical Face Masks as Third Wave of COVID-19 Surges

Beyond Medical Technologies Inc. (" Beyond Medical " or the " Company ") (CSE: DOCT) ( Frankfurt : 7FM4) is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. (" Micron Technologies ").

Taking Healthcare Beyond Traditional Platforms (CNW Group/Beyond Medical Technologies Inc.)

Manufacturing Three-Ply Medical Grade Face Masks at Full Capacity

Micron Technologies has been manufacturing and selling three-ply medical grade face masks at the Company's facility in Delta, British Columbia since August 2020 . The three-ply medical grade face masks are being manufactured pursuant to Micron Technologies' Medical Device Establishment License issued by Health Canada. The three-ply medical grade face masks offer three layers of protection, which conforms to the American Society for Testing and Materials' F2100 Level 3 standards. The non-woven masks feature an adjustable nose clip designed to protect both front-line workers and consumers. Micron Technologies is currently operating three shifts a day to manufacture three-ply medical grade face masks.

Manufacturing N95 Face Masks

Micron Technologies is now also setting up manufacturing N95 Model 8800 face masks, which have been approved.  Micron Technologies has submitted its N95 Model 8800 face masks to the National Institute for Occupational Safety and Health (" NIOSH ") and is confident it will obtain NIOSH certification as its N95 Model 8800 face masks have already passed testing with Kinetrics Analytical and Environmental Laboratories. Micron Technologies has purchased a large quantity of raw materials to manufacture N95 Model 8800 face masks and plans to maximize production efforts once NIOSH certification has been obtained. As of last month there was still a significant shortage of N95 masks and approximately " 56 percent of frontline workers say they still don't have enough N95 masks. "

Third Wave of COVID-19

According to Dr. Abdu Sharkawy , an infectious disease specialist, the third wave of COVID-19 is " likely going to be worse than the first two ." With respect to the addition of variants, Dr. Sharkawy noted " and of course we've seen what these variants can offer, they can really lead to an explosion of cases very quickly ."  Dr. Theresa Tam , Canada's Chief Public Health Officer, announced a 64% increase in new cases involving variants. In addition to the new variants, the slow vaccine roll-out and complacency with public health restrictions are contributing to the third wave.

Earlier this month Canada surpassed 1,000,000 confirmed COVID-19 cases since the beginning of the pandemic, with the provinces of Ontario , Quebec , and British Columbia being hit the hardest by the third wave.

Products Now Available at Walmart

As previously announced, Micron Technologies' three-ply medical grade face masks and N95 medical grade face masks have been approved for sale by Walmart. Micron Technologies expects its products to be available at www.walmart.com in the coming weeks.

In addition to Walmart, Micron Technologies' products are also available on Amazon and Shopify. Institutional customers and those who are interested in obtaining a quote for large size orders are encouraged to contact Milan@micronti.com . Customers can also make orders directly at https://micronti.com .

About Beyond Medical

Beyond Medical is an industrial/technology company with a manufacturing facility located in Delta, British Columbia . The Company is developing its Organivore and Pharmavore waste digesters using its proprietary technology. The Company, through its subsidiary Micron Technologies, is also manufacturing medical grade face masks.

The Company is not making any express or implied claims that its products have the ability to eliminate, cure or contain COVID-19 (or SARS-2 Coronavirus) at this time.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release. The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.

FORWARD LOOKING STATEMENTS:

This news release includes certain statements that may be deemed "forward-looking statements". All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

SOURCE Beyond Medical Technologies Inc.

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/April2021/07/c7788.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Beyond Medical subsidiary Micron Technologies begins Sales of Made in Canada Face Masks to Walmart

Beyond Medical subsidiary Micron Technologies begins Sales of Made in Canada Face Masks to Walmart

Beyond Medical Technologies Inc. (" Beyond Medical " or the " Company ") (CSE: DOCT) ( Frankfurt : 7FM4) is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. (" Micron Technologies ").

Taking Healthcare Beyond Traditional Platforms (CNW Group/Beyond Medical Technologies Inc.)

Products Now Available at Walmart

Micron Technologies' three-ply medical grade face masks and N95 medical grade face masks have been approved for sale by Walmart. Micron Technologies has completed the onboarding process and its products will be available at www.walmart.com by the beginning of April 2021 .

Kal Malhi , CEO of Beyond Medical states: "We are pleased to offer our products to loyal Walmart customers at competitive prices. The availability of our product with one of the largest retailers in the world will bring significant exposure to our made-in- Canada medical face mask brand.  Our recently completed capital raise will allow us to ramp up manufacturing to meet new demand from Walmart customers."

In addition to Walmart, Micron Technologies' products are also available on Amazon and Shopify. Institutional customers and those who are interested in obtaining a quote for large size orders are encouraged to contact Milan@micronti.com .

Three-Ply Medical Grade Face Masks

Micron Technologies has been manufacturing and selling three-ply medical grade face masks since August 2020 . The masks are available in the colour blue and black. The majority of Micron Technologies' sales have been to provincial governments; however, sales are also being completed online to various other customers. Micron Technologies is considering acquiring additional manufacturing equipment and hiring more personnel as it is currently operating at full capacity and continues to sell out of inventory.

N95 Face Masks

In addition to the three-ply medical grade face masks, Micron Technologies is also manufacturing N95 Model 8800 face masks. Micron Technologies' N95 Model 8800 face masks have been approved by Health Canada and the US Food and Drug Administration. Additionally, the N95 Model 8800 face masks have passed testing with Kinetrics Analytical and Environmental Laboratories. Accordingly, Micron Technologies is confident that its N95 Model 8800 face masks will obtain medical-grade certification from the National Institute for Occupational Safety and Health in the coming weeks.  There are currently a limited number of NIOSH approved medical face mask manufacturers and the demand for these masks in outpacing supply.

On February 2,2012 , Washington Post reported on N95 masks: "The initial shortage has eased, but there still aren't enough medical masks for health-care workers, let alone others. Demand for N95s is 500 to 1,000 percent higher than it was a year ago, said Megan Ranney , co-founder of Get Us PPE, which helps front-line workers obtain personal protective equipment."

Last month President Biden's chief medical advisor for Covid-19, Dr. Anthony Fauci , indicated that Americans may still be wearing masks in 2023, as mask-wearing has been critical in slowing down the spread Covid-19. N95 masks are the gold standard of personal protective equipment, particularly among healthcare professionals as they provide the highest level of protection for the user and those in close proximity. Beyond Medical hopes to have its N95 Model 8800 face masks certified as soon as possible in an effort to reduce the spread of Covid-19.

About Beyond Medical

Beyond Medical is an industrial/technology company with a manufacturing facility located in Delta, BC . The Company is developing its Organivore and Pharmavore waste digesters using its proprietary technology. The Company, through its subsidiary Micron Technologies, is also manufacturing medical grade face masks.

The Company is not making any express or implied claims that its products have the ability to eliminate, cure or contain COVID-19 (or SARS-2 Coronavirus) at this time.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release. The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.

FORWARD LOOKING STATEMENTS:

This news release includes certain statements that may be deemed "forward-looking statements". All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

SOURCE Beyond Medical Technologies Inc.

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/March2021/30/c9088.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
  BPH Global Ltd

Notice of Extraordinary General Meeting/Proxy Form

Notice is hereby given that an Extraordinary General Meeting of Shareholders of BPH Global Limited ACN 009 104 330 will be held at 3:00pm AEST on 24 May 2024 at Suite 5, Level 12, 530 Collins Street, Melbourne VIC 3000 (Meeting).

Keep reading...Show less
Genes and chromosomes with "2024" overlay.

Biotech Market Update: Q1 2024 in Review

The first quarter of 2024 witnessed a surge in initial public offerings (IPOs) and mergers and acquisitions (M&A) within the biotech industry, signaling continued interest from investors.

AstraZeneca’s acquisition of start-up Amolyt on March 14, and its longtime biotech partner Fusion Pharmaceuticals for US$2.4 billion on March 19 marked the third acquisition of a radiopharmaceutical developer in recent months. As of writing, there have been 14 M&A deals struck in 2024, according to data from Biopharma Dive.

Investment bank Jefferies released data in early March revealing that the sector was on track to earn its highest quarterly total in three years, reflecting the cautiously optimistic outlook at this year's JPM24 conference.

Keep reading...Show less

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

Planning Underway for Phase 3 Development of Tezepelumab in COPD

Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE ® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20 from 9:15-11:15 a.m. PDT .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Close up 3D rendering of DNA strands.

Biotech Stocks: 5 Biggest Companies in 2024

What are the top biotech companies? The following five stocks have market capitalizations worth billions of dollars and operate in countries all around the globe.

Plus, these big-name biotech players have pipelines stuffed with potentially disruptive products — and enough revenue to recover should some of those products fail.

This means that investors can experience the excitement of biotech investing while minimizing risk. Although returns are never guaranteed, company size can insulate investors from volatility.

Keep reading...Show less
SIRONA BIOCHEM Corporate Update April 2024

SIRONA BIOCHEM Corporate Update April 2024

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") provides the following update:

Dear shareholders,

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Announces Close of Private Placement

Sirona Biochem Announces Close of Private Placement

Vancouver, British Columbia – April 4, 2024 Sirona Biochem Corp . (TSX-V: SBM) (Frankfurt: ZSB) (" Sirona ") has closed its private placement (Private Placement") for gross proceeds of $132,500 CAD. The Private Placement consists of 1,325,000 units, (the "Units") at a price of $0.10 per Unit. Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of issue at a price of $0.15 per Share in year one and $0.25 per Share in year two. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×